Portfolio prioritization and optimization
The challenge
A clinical-stage biopharmaceutical company sought to develop an optimized portfolio strategy. It sought Putnam’s guidance to prioritize asset-level strategies through a holistic review of options.
Our solution
We generated a comprehensive list of asset opportunities and portfolio options and prioritized 18 programs by applying pre-agreed criteria, defining the value of each opportunity, creating revenue streams with market criteria, and facilitating working sessions to align on critical assumptions.
The results
Our portfolio recommendations addressed the enterprise goals of being best-in-class, maximizing economic value, achieving optimal timing, and minimizing risk over time and across geographies.
Jump to a slide with the slide dots.
CNS indication/ Endpoint prioritization
A biopharma client with an early clinical stage compound, showing efficacy across multiple neuropsychiatric conditions, wished to prioritize...
Read moreMedical Affairs omnichannel platform
A large biopharma client objective aimed to optimize its omnichannel (OC) approach for HCP and patient Medical Education...
Read moreRare respiratory claims data analysis
A top biopharma client wanted to understand diagnosis and treatment patterns for a rare respiratory disease only recently associated as a sequela....
Read more